Product Overview

HapOnco^® Lung Cancer BasicPanel™ NGS Assay is an NGS-based assay for lung cancer patients to guide therapy selection. It detects 11 lung cancer-related genes, including 8 NCCN-recommended targetable driver genes and 3 genes critical to lung cancer development, as well as 29 SNP loci associated with chemotherapy responses and side effects. The HapOnco^® Lung Cancer BasicPanel™ NGS Assay focuses on the sensitivity of essential targeted drugs and can offer comprehensive reference data for targeted treatments and prognostic assessments for lung cancer patients.

Product Overview

HapOnco^® Colorectal Cancer BasicPanel™ NGS Assay covers 23 genes relating to the efficacy of targeted therapies for colorectal cancer, including the entire protein-coding regions of all driver genes with targetable mutations as recommended by NCCN (23 genes) and 7 fusion variants. The gene panel of this assay also includes 25 SNP loci related to chemotherapy responses and side effects. HapOnco^® Colorectal Cancer BasicPanel™ NGS Assay provides comprehensive guidance for clinical use in terms of targeted therapy and prognosis assessment.

Product Overview

HapOnco^® Thyroid Cancer BasicPanel™ NGS Assay enables patients and physicians to make informed selections of the best treatment option and avoid unnecessary surgery by analyzing the entire protein-coding regions of 35 genes and 35 fusion variants, as well as 31 CNVs, to detect the genetic variants most commonly associated with thyroid cancer and medullary thyroid cancer.

Product Overview

HapOnco^® Glioma BasicPanel™ NGS Assay covers 16 types of glioma-related genomic alterations, including CNVs, gene fusions, promoter methylation and chromosomal variation. The gene panel includes IDH1 and IDH2, mutations of which occur in a mutually exclusive manner. HapOnco^® Glioma BasicPanel™ NGS Assay provides information for molecular sub-typing, prognosis assessment, targeted drug selection and precision clinical diagnosis for glioma patients.